CA2442340A1 - Proceder pour limiter la formation de cicatrices et d'adherences - Google Patents

Proceder pour limiter la formation de cicatrices et d'adherences Download PDF

Info

Publication number: CA2442340A1
Authority: CA; Canada
Prior art keywords: use according; aii; pro; artificial sequence; tyr
Prior art date: 1999-03-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002442340A

Other languages

English (en)

Inventor

Kathleen Rodgers

Gere Dizerega

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of Southern California USC

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-03-23

Filing date

2000-03-22

Publication date

2000-09-28

2000-03-22 Application filed by Individual filed Critical Individual

2000-03-22 Priority claimed from CA002367107A external-priority patent/CA2367107C/fr

2000-09-28 Publication of CA2442340A1 publication Critical patent/CA2442340A1/fr

Status Abandoned legal-status Critical Current

Links

231100000241 scar Toxicity 0.000 title claims abstract description 42
230000015572 biosynthetic process Effects 0.000 title claims abstract description 40
238000000034 method Methods 0.000 title abstract description 27
208000027418 Wounds and injury Diseases 0.000 claims description 56
206010052428 Wound Diseases 0.000 claims description 45
239000013543 active substance Substances 0.000 claims description 39
238000001356 surgical procedure Methods 0.000 claims description 28
230000036573 scar formation Effects 0.000 claims description 25
150000001413 amino acids Chemical class 0.000 claims description 21
208000014674 injury Diseases 0.000 claims description 13
208000032544 Cicatrix Diseases 0.000 claims description 9
230000037387 scars Effects 0.000 claims description 9
125000003798 L-tyrosyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 claims description 6
UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 claims description 5
238000002350 laparotomy Methods 0.000 claims description 5
NILQLFBWTXNUOE-UHFFFAOYSA-N 1-aminocyclopentanecarboxylic acid Chemical compound OC(=O)C1(N)CCCC1 NILQLFBWTXNUOE-UHFFFAOYSA-N 0.000 claims description 4
ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 claims description 4
KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims description 4
208000006111 contracture Diseases 0.000 claims description 4
230000001969 hypertrophic effect Effects 0.000 claims description 4
238000002360 preparation method Methods 0.000 claims description 4
210000002435 tendon Anatomy 0.000 claims description 4
240000004307 Citrus medica Species 0.000 claims description 3
208000034693 Laceration Diseases 0.000 claims description 3
239000003814 drug Substances 0.000 claims description 3
210000003041 ligament Anatomy 0.000 claims description 3
230000000926 neurological effect Effects 0.000 claims description 3
206010016654 Fibrosis Diseases 0.000 claims description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 2
206010023330 Keloid scar Diseases 0.000 claims description 2
125000000010 L-asparaginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(=O)N([H])[H] 0.000 claims description 2
125000003338 L-glutaminyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C(=O)N([H])[H] 0.000 claims description 2
208000025865 Ulcer Diseases 0.000 claims description 2
239000002537 cosmetic Substances 0.000 claims description 2
230000004761 fibrosis Effects 0.000 claims description 2
230000002068 genetic effect Effects 0.000 claims description 2
230000003239 periodontal effect Effects 0.000 claims description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 2
230000008733 trauma Effects 0.000 claims description 2
231100000397 ulcer Toxicity 0.000 claims description 2
206010000050 Abdominal adhesions Diseases 0.000 claims 1
206010034238 Pelvic adhesions Diseases 0.000 claims 1
150000001875 compounds Chemical class 0.000 abstract description 27
239000012634 fragment Substances 0.000 abstract description 17
102000004881 Angiotensinogen Human genes 0.000 abstract description 8
108090001067 Angiotensinogen Proteins 0.000 abstract description 8
239000005541 ACE inhibitor Substances 0.000 abstract description 7
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 abstract description 7
229940044601 receptor agonist Drugs 0.000 abstract description 7
239000000018 receptor agonist Substances 0.000 abstract description 7
239000008194 pharmaceutical composition Substances 0.000 abstract description 4
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 131
101800000733 Angiotensin-2 Proteins 0.000 description 67
102400000345 Angiotensin-2 Human genes 0.000 description 67
229950006323 angiotensin ii Drugs 0.000 description 67
ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 30
108090000765 processed proteins & peptides Proteins 0.000 description 29
230000000694 effects Effects 0.000 description 28
210000001519 tissue Anatomy 0.000 description 20
230000035876 healing Effects 0.000 description 18
101800000734 Angiotensin-1 Proteins 0.000 description 17
102400000344 Angiotensin-1 Human genes 0.000 description 17
102000004196 processed proteins & peptides Human genes 0.000 description 17
108010085325 histidylproline Proteins 0.000 description 16
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 14
102000005962 receptors Human genes 0.000 description 14
108020003175 receptors Proteins 0.000 description 14
239000000203 mixture Substances 0.000 description 13
ANAHQDPQQBDOBM-UHFFFAOYSA-N Arg-Val-Tyr Natural products CC(C)C(NC(=O)C(N)CCNC(=N)N)C(=O)NC(Cc1ccc(O)cc1)C(=O)O ANAHQDPQQBDOBM-UHFFFAOYSA-N 0.000 description 11
230000006378 damage Effects 0.000 description 11
230000029663 wound healing Effects 0.000 description 11
206010020772 Hypertension Diseases 0.000 description 10
241000700159 Rattus Species 0.000 description 10
229920002134 Carboxymethyl cellulose Polymers 0.000 description 9
241000283973 Oryctolagus cuniculus Species 0.000 description 9
235000010948 carboxy methyl cellulose Nutrition 0.000 description 9
210000004027 cell Anatomy 0.000 description 9
230000037390 scarring Effects 0.000 description 9
210000003491 skin Anatomy 0.000 description 9
WHLDJYNHXOMGMU-JYJNAYRXSA-N Arg-Val-Tyr Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 WHLDJYNHXOMGMU-JYJNAYRXSA-N 0.000 description 8
XYBJLTKSGFBLCS-QXEWZRGKSA-N Asp-Arg-Val Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@@H](N)CC(O)=O XYBJLTKSGFBLCS-QXEWZRGKSA-N 0.000 description 8
230000009885 systemic effect Effects 0.000 description 8
230000037396 body weight Effects 0.000 description 7
-1 ceranopril Chemical compound 0.000 description 7
230000009467 reduction Effects 0.000 description 7
UCHGVQMTIJAUOM-RSGBUPOYSA-N (2s)-2-[[(2s)-1-[(2s)-2-[[(2s,3s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid Chemical compound C([C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 UCHGVQMTIJAUOM-RSGBUPOYSA-N 0.000 description 6
FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 6
PBVQWNDMFFCPIZ-ULQDDVLXSA-N His-Pro-Phe Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CN=CN1 PBVQWNDMFFCPIZ-ULQDDVLXSA-N 0.000 description 6
238000009472 formulation Methods 0.000 description 6
229910052739 hydrogen Inorganic materials 0.000 description 6
239000000843 powder Substances 0.000 description 6
238000011282 treatment Methods 0.000 description 6
230000002500 effect on skin Effects 0.000 description 5
239000001257 hydrogen Substances 0.000 description 5
230000002980 postoperative effect Effects 0.000 description 5
QSBGWDDCOJYQGY-KOQODJNWSA-N Angiotensin IV Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)C(C)C)C1=CC=C(O)C=C1 QSBGWDDCOJYQGY-KOQODJNWSA-N 0.000 description 4
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
210000003815 abdominal wall Anatomy 0.000 description 4
239000002671 adjuvant Substances 0.000 description 4
230000003110 anti-inflammatory effect Effects 0.000 description 4
230000008021 deposition Effects 0.000 description 4
210000002744 extracellular matrix Anatomy 0.000 description 4
210000002950 fibroblast Anatomy 0.000 description 4
230000014509 gene expression Effects 0.000 description 4
230000002209 hydrophobic effect Effects 0.000 description 4
239000000463 material Substances 0.000 description 4
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
210000000056 organ Anatomy 0.000 description 4
230000002265 prevention Effects 0.000 description 4
230000008439 repair process Effects 0.000 description 4
238000007920 subcutaneous administration Methods 0.000 description 4
239000003981 vehicle Substances 0.000 description 4
101150116411 AGTR2 gene Proteins 0.000 description 3
NMXKFWOEASXOGB-QSFUFRPTSA-N Ala-Ile-His Chemical compound C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 NMXKFWOEASXOGB-QSFUFRPTSA-N 0.000 description 3
241000024188 Andala Species 0.000 description 3
DBWYWXNMZZYIRY-LPEHRKFASA-N Asp-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)O)N)C(=O)O DBWYWXNMZZYIRY-LPEHRKFASA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 3
PVHLMTREZMEJCG-GDTLVBQBSA-N Ile(5)-angiotensin II (1-7) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 PVHLMTREZMEJCG-GDTLVBQBSA-N 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
206010060932 Postoperative adhesion Diseases 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
102000003978 Tissue Plasminogen Activator Human genes 0.000 description 3
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 3
102000009618 Transforming Growth Factors Human genes 0.000 description 3
108010009583 Transforming Growth Factors Proteins 0.000 description 3
230000009471 action Effects 0.000 description 3
239000000556 agonist Substances 0.000 description 3
230000004075 alteration Effects 0.000 description 3
229920002678 cellulose Polymers 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
230000023753 dehiscence Effects 0.000 description 3
WOIWWYDXDVSWAZ-RTWAWAEBSA-N fosinoprilat Chemical compound C([C@@H](C[C@H]1C(=O)O)C2CCCCC2)N1C(=O)CP(O)(=O)CCCCC1=CC=CC=C1 WOIWWYDXDVSWAZ-RTWAWAEBSA-N 0.000 description 3
230000012010 growth Effects 0.000 description 3
229960001680 ibuprofen Drugs 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
239000007788 liquid Substances 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
230000008569 process Effects 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000007790 solid phase Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
229960000187 tissue plasminogen activator Drugs 0.000 description 3
230000000699 topical effect Effects 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
DUEUCUPESSMDMI-VVKHCXNMSA-N (2s)-1-[(2s)-2-[[(2s,3s)-2-[[(2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]pyrrolidine-2-carboxylic acid Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(O)=O)NC(=O)[C@@H](N)C(C)C)C1=CC=C(O)C=C1 DUEUCUPESSMDMI-VVKHCXNMSA-N 0.000 description 2
BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
IQMHGRIOYXVPSE-UHFFFAOYSA-N 2-acetamido-5-[formyl(hydroxy)amino]-n-[1-[3-[5-[3-[formyl(hydroxy)amino]propyl]-3,6-dioxopiperazin-2-yl]propyl-hydroxyamino]-3-hydroxy-1-oxopropan-2-yl]pentanamide Chemical compound O=CN(O)CCCC(NC(=O)C)C(=O)NC(CO)C(=O)N(O)CCCC1NC(=O)C(CCCN(O)C=O)NC1=O IQMHGRIOYXVPSE-UHFFFAOYSA-N 0.000 description 2
IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
CMUHFUGDYMFHEI-QMMMGPOBSA-N 4-amino-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N)C=C1 CMUHFUGDYMFHEI-QMMMGPOBSA-N 0.000 description 2
102000015427 Angiotensins Human genes 0.000 description 2
108010064733 Angiotensins Proteins 0.000 description 2
KGSJCPBERYUXCN-BPNCWPANSA-N Arg-Ala-Tyr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O KGSJCPBERYUXCN-BPNCWPANSA-N 0.000 description 2
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
208000032843 Hemorrhage Diseases 0.000 description 2
LNCFUHAPNTYMJB-IUCAKERBSA-N His-Pro Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CN=CN1 LNCFUHAPNTYMJB-IUCAKERBSA-N 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
WRLPVDVHNWSSCL-MELADBBJSA-N Leu-His-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@@H]2C(=O)O)N WRLPVDVHNWSSCL-MELADBBJSA-N 0.000 description 2
BWRVBFMWWHWLBW-UHFFFAOYSA-N Lyciumin B Chemical compound C12=CC=CC=C2N2C=C1CC(C(O)=O)NC(=O)C(CO)NC(=O)CNC(=O)C(C(C)C)NC(=O)C2NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCCN1C(=O)C1CCC(=O)N1 BWRVBFMWWHWLBW-UHFFFAOYSA-N 0.000 description 2
IWIANZLCJVYEFX-RYUDHWBXSA-N Pro-Phe Chemical compound C([C@@H](C(=O)O)NC(=O)[C@H]1NCCC1)C1=CC=CC=C1 IWIANZLCJVYEFX-RYUDHWBXSA-N 0.000 description 2
102100028255 Renin Human genes 0.000 description 2
108090000783 Renin Proteins 0.000 description 2
241000283984 Rodentia Species 0.000 description 2
206010039509 Scab Diseases 0.000 description 2
VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 2
DZKFGCNKEVMXFA-JUKXBJQTSA-N Tyr-Ile-His Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O DZKFGCNKEVMXFA-JUKXBJQTSA-N 0.000 description 2
208000024248 Vascular System injury Diseases 0.000 description 2
208000012339 Vascular injury Diseases 0.000 description 2
230000003187 abdominal effect Effects 0.000 description 2
NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 2
229960005054 acepromazine Drugs 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
230000032683 aging Effects 0.000 description 2
230000000202 analgesic effect Effects 0.000 description 2
238000013459 approach Methods 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
229960002537 betamethasone Drugs 0.000 description 2
UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
239000008112 carboxymethyl-cellulose Substances 0.000 description 2
210000004534 cecum Anatomy 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
239000003246 corticosteroid Substances 0.000 description 2
229960001334 corticosteroids Drugs 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
230000002939 deleterious effect Effects 0.000 description 2
229960003957 dexamethasone Drugs 0.000 description 2
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 2
229960002768 dipyridamole Drugs 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
230000001605 fetal effect Effects 0.000 description 2
235000013305 food Nutrition 0.000 description 2
229960002490 fosinopril Drugs 0.000 description 2
KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 2
208000021267 infertility disease Diseases 0.000 description 2
230000028709 inflammatory response Effects 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
208000003243 intestinal obstruction Diseases 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
208000028867 ischemia Diseases 0.000 description 2
210000002510 keratinocyte Anatomy 0.000 description 2
229960003299 ketamine Drugs 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
229960000901 mepacrine Drugs 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
230000008520 organization Effects 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
239000000816 peptidomimetic Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
229940068196 placebo Drugs 0.000 description 2
239000000902 placebo Substances 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
GPKJTRJOBQGKQK-UHFFFAOYSA-N quinacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 description 2
239000002464 receptor antagonist Substances 0.000 description 2
229940044551 receptor antagonist Drugs 0.000 description 2
TVTJZMHAIQQZTL-WATAJHSMSA-M sodium;(2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylate Chemical compound [Na+].C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C([O-])=O)CCCC1=CC=CC=C1 TVTJZMHAIQQZTL-WATAJHSMSA-M 0.000 description 2
239000000243 solution Substances 0.000 description 2
229960002909 spirapril Drugs 0.000 description 2
108700035424 spirapril Proteins 0.000 description 2
HRWCVUIFMSZDJS-SZMVWBNQSA-N spirapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2(C1)SCCS2)C(O)=O)CC1=CC=CC=C1 HRWCVUIFMSZDJS-SZMVWBNQSA-N 0.000 description 2
229960004084 temocapril Drugs 0.000 description 2
FIQOFIRCTOWDOW-BJLQDIEVSA-N temocapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C[C@H](SC1)C=1SC=CC=1)=O)CC1=CC=CC=C1 FIQOFIRCTOWDOW-BJLQDIEVSA-N 0.000 description 2
238000012360 testing method Methods 0.000 description 2
210000000115 thoracic cavity Anatomy 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
DEEOVDONDDERBX-MUDWFXPSSA-N (2S)-6-amino-2-[[(1S,4R,10S,19S,22S,25S,28S,31S,34R,37S,43S,46S,47S,50R,53S,56S,62S)-50-amino-43-(2-amino-2-oxoethyl)-56-(3-amino-3-oxopropyl)-10-benzyl-37-(carboxymethyl)-31-(hydroxymethyl)-28-(1H-indol-3-ylmethyl)-47,62-dimethyl-7-methylidene-22-(2-methylpropyl)-2,5,8,11,14,20,23,26,29,32,35,38,41,44,51,54,57-heptadecaoxo-53-propan-2-yl-48,60,63-trithia-3,6,9,12,15,21,24,27,30,33,36,39,42,45,52,55,58-heptadecazatetracyclo[32.24.3.34,25.015,19]tetrahexacontane-46-carbonyl]amino]hexanoic acid Chemical compound CC(C)C[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)C(=C)NC(=O)[C@@H]2CS[C@@H](C)[C@@H](NC1=O)C(=O)N[C@@H](Cc1c[nH]c3ccccc13)C(=O)N[C@@H](CO)C(=O)N[C@H]1CSC[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CS[C@@H](C)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC1=O)C(=O)N[C@@H](CCCCN)C(O)=O)C(C)C)C(=O)N2 DEEOVDONDDERBX-MUDWFXPSSA-N 0.000 description 1
NVXFXLSOGLFXKQ-JMSVASOKSA-N (2s)-1-[(2r,4r)-5-ethoxy-2,4-dimethyl-5-oxopentanoyl]-2,3-dihydroindole-2-carboxylic acid Chemical compound C1=CC=C2N(C(=O)[C@H](C)C[C@@H](C)C(=O)OCC)[C@H](C(O)=O)CC2=C1 NVXFXLSOGLFXKQ-JMSVASOKSA-N 0.000 description 1
QIJLJZOGPPQCOG-NFAWXSAZSA-N (2s)-1-[(2s)-3-[(2r)-2-(cyclohexanecarbonylamino)propanoyl]sulfanyl-2-methylpropanoyl]pyrrolidine-2-carboxylic acid Chemical compound N([C@H](C)C(=O)SC[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(=O)C1CCCCC1 QIJLJZOGPPQCOG-NFAWXSAZSA-N 0.000 description 1
QHRDRNITQKNXNS-JGYLIOAXSA-N (2s)-10-[[(2r)-1-[[(2s)-2-[2-[(2s,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoylamino]propanoyl]-[(1r)-1-carboxyethyl]amino]-1-oxopropan-2-yl]amino]-2,9-diamino-6-(1,2-diamino-2-oxoethyl)-5,10-dioxodecanoic acid Chemical compound OC(=O)[C@@H](N)CCC(=O)C(C(N)C(N)=O)CCC(N)C(=O)N[C@H](C)C(=O)N([C@H](C)C(O)=O)C(=O)[C@H](C)NC(=O)C(C)O[C@H]1[C@H](O)[C@@H](CO)O[C@H](O)[C@@H]1NC(C)=O QHRDRNITQKNXNS-JGYLIOAXSA-N 0.000 description 1
PHASTBJLWIZXKB-KKSFZXQISA-N (2s)-2-[[(2s)-1-[carboxymethyl(2,3-dihydro-1h-inden-2-yl)amino]-1-oxopropan-2-yl]amino]-4-phenylbutanoic acid Chemical compound C([C@H](N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 PHASTBJLWIZXKB-KKSFZXQISA-N 0.000 description 1
GKYIONYOYVKKQI-MPGHIAIKSA-N (2s)-2-[[(2s,3r)-2-(benzoylsulfanylmethyl)-3-phenylbutanoyl]amino]propanoic acid Chemical compound C([C@H](C(=O)N[C@@H](C)C(O)=O)[C@@H](C)C=1C=CC=CC=1)SC(=O)C1=CC=CC=C1 GKYIONYOYVKKQI-MPGHIAIKSA-N 0.000 description 1
HBZJVGFXZTUXNI-XMQLQKOFSA-N (2s)-3-[(2s)-2-[[(1s)-1-carboxy-3-phenylpropyl]amino]propanoyl]-3-azabicyclo[2.2.2]octane-2-carboxylic acid Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](C2CCC1CC2)C(O)=O)C(O)=O)CC1=CC=CC=C1 HBZJVGFXZTUXNI-XMQLQKOFSA-N 0.000 description 1
OMGPCTGQLHHVDU-SSXGPBTGSA-N (2s)-3-[(2s)-2-[[(2s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3-azabicyclo[2.2.2]octane-2-carboxylic acid Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C2CCC1CC2)C(O)=O)CC1=CC=CC=C1 OMGPCTGQLHHVDU-SSXGPBTGSA-N 0.000 description 1
FTYVYAGWBXTWTN-ZVZYQTTQSA-N (2s)-5-tert-butyl-3-[(2s)-2-[[(2s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-2h-1,3,4-thiadiazole-2-carboxylic acid Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](SC(=N1)C(C)(C)C)C(O)=O)CC1=CC=CC=C1 FTYVYAGWBXTWTN-ZVZYQTTQSA-N 0.000 description 1
AHYHTSYNOHNUSH-GBBGEASQSA-N (2s,3as,7as)-1-[(2s)-2-[[(1s)-1-carboxy-3-phenylpropyl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCCC[C@@H]21)C(O)=O)C(O)=O)CC1=CC=CC=C1 AHYHTSYNOHNUSH-GBBGEASQSA-N 0.000 description 1
CMPAGYDKASJORH-YSSFQJQWSA-N (3s)-2-[(2s)-2-[[(1s)-1-carboxy-3-phenylpropyl]amino]propanoyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinoline-3-carboxylic acid Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](CC=2C=C(C(=CC=2C1)OC)OC)C(O)=O)C(O)=O)CC1=CC=CC=C1 CMPAGYDKASJORH-YSSFQJQWSA-N 0.000 description 1
GXYZOEYEQZDXJK-JPGDYHFISA-N (3s)-3-[[2-[[(2s)-1-[(2s)-2-aminopropanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-4-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxy-2-phenylethyl]carbamoyl]pyrrolidin-1-yl]-3-(4h-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl Chemical compound N([C@@H](CC(O)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N GXYZOEYEQZDXJK-JPGDYHFISA-N 0.000 description 1
NZFXQRHFBLVEQA-GXOSTJLWSA-N (6r)-2-[[(4s)-4-[[(2s)-2-[2-[(2s,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoylamino]propanoyl]amino]-4-carboxybutanoyl]amino]-6,7-diamino-7-oxoheptanoic acid Chemical compound NC(=O)[C@H](N)CCCC(C(O)=O)NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)C(C)O[C@H]1[C@H](O)[C@@H](CO)O[C@H](O)[C@@H]1NC(C)=O NZFXQRHFBLVEQA-GXOSTJLWSA-N 0.000 description 1
FAKRSMQSSFJEIM-BQBZGAKWSA-N 1-(3-mercapto-2-methyl-propionyl)-pyrrolidine-2-carboxylic acid Chemical compound SC[C@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-BQBZGAKWSA-N 0.000 description 1
IFYLTXNCFVRALQ-UHFFFAOYSA-N 1-[6-amino-2-[hydroxy(4-phenylbutyl)phosphoryl]oxyhexanoyl]pyrrolidine-2-carboxylic acid Chemical compound C1CCC(C(O)=O)N1C(=O)C(CCCCN)OP(O)(=O)CCCCC1=CC=CC=C1 IFYLTXNCFVRALQ-UHFFFAOYSA-N 0.000 description 1
CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
XRKXJJYSKUIIEN-UHFFFAOYSA-N 2-[cyclopentyl-[3-(2,2-dimethylpropanoylsulfanyl)-2-methylpropanoyl]amino]acetic acid Chemical compound CC(C)(C)C(=O)SCC(C)C(=O)N(CC(O)=O)C1CCCC1 XRKXJJYSKUIIEN-UHFFFAOYSA-N 0.000 description 1
ZAEAFACGXYFJRC-UHFFFAOYSA-N 2-[methyl-[2-(methylazaniumyl)acetyl]amino]acetate Chemical compound CNCC(=O)N(C)CC(O)=O ZAEAFACGXYFJRC-UHFFFAOYSA-N 0.000 description 1
UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
108010023336 7-Ala-angiotensin (1-7) Proteins 0.000 description 1
101150059573 AGTR1 gene Proteins 0.000 description 1
HUUOZYZWNCXTFK-INTQDDNPSA-N Ala-His-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@@H]2C(=O)O)N HUUOZYZWNCXTFK-INTQDDNPSA-N 0.000 description 1
FHHHOYXPRDYHEZ-COXVUDFISA-N Alacepril Chemical compound CC(=O)SC[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 FHHHOYXPRDYHEZ-COXVUDFISA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
QMMRCKSBBNJCMR-KMZPNFOHSA-N Angiotensin III Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCN=C(N)N)C(C)C)C1=CC=C(O)C=C1 QMMRCKSBBNJCMR-KMZPNFOHSA-N 0.000 description 1
101800000738 Angiotensin-3 Proteins 0.000 description 1
102400000348 Angiotensin-3 Human genes 0.000 description 1
IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical class NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 1
PSZNHSNIGMJYOZ-WDSKDSINSA-N Asp-Arg Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N PSZNHSNIGMJYOZ-WDSKDSINSA-N 0.000 description 1
SDHFVYLZFBDSQT-DCAQKATOSA-N Asp-Arg-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)O)N SDHFVYLZFBDSQT-DCAQKATOSA-N 0.000 description 1
OAMLVOVXNKILLQ-BQBZGAKWSA-N Asp-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(O)=O OAMLVOVXNKILLQ-BQBZGAKWSA-N 0.000 description 1
MYLZFUMPZCPJCJ-NHCYSSNCSA-N Asp-Lys-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O MYLZFUMPZCPJCJ-NHCYSSNCSA-N 0.000 description 1
206010003497 Asphyxia Diseases 0.000 description 1
XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
NEEBNBLVYKFVTK-VGMNWLOBSA-N Captopril-cysteine disulfide Chemical compound OC(=O)[C@@H](N)CSSC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O NEEBNBLVYKFVTK-VGMNWLOBSA-N 0.000 description 1
IFYLTXNCFVRALQ-OALUTQOASA-N Ceronapril Chemical compound O([C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)P(O)(=O)CCCCC1=CC=CC=C1 IFYLTXNCFVRALQ-OALUTQOASA-N 0.000 description 1
UVAUYSRYXACKSC-ULQDDVLXSA-N Cilazaprilat Chemical compound C([C@@H](C(=O)O)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 UVAUYSRYXACKSC-ULQDDVLXSA-N 0.000 description 1
206010009269 Cleft palate Diseases 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
208000032170 Congenital Abnormalities Diseases 0.000 description 1
229920001651 Cyanoacrylate Polymers 0.000 description 1
241001269524 Dura Species 0.000 description 1
108010061435 Enalapril Proteins 0.000 description 1
108010066671 Enalaprilat Proteins 0.000 description 1
KQXVERRYBYGQJZ-WRPDIKACSA-N Enalkiren Chemical compound C1=CC(OC)=CC=C1C[C@H](NC(=O)CC(C)(C)N)C(=O)N[C@H](C(=O)N[C@@H](CC1CCCCC1)[C@@H](O)[C@@H](O)CC(C)C)CC1=CN=CN1 KQXVERRYBYGQJZ-WRPDIKACSA-N 0.000 description 1
108010073385 Fibrin Proteins 0.000 description 1
102000009123 Fibrin Human genes 0.000 description 1
108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
MPZWMIIOPAPAKE-BQBZGAKWSA-N Glu-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N MPZWMIIOPAPAKE-BQBZGAKWSA-N 0.000 description 1
DYFJZDDQPNIPAB-NHCYSSNCSA-N Glu-Arg-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O DYFJZDDQPNIPAB-NHCYSSNCSA-N 0.000 description 1
BBBXWRGITSUJPB-YUMQZZPRSA-N Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(O)=O BBBXWRGITSUJPB-YUMQZZPRSA-N 0.000 description 1
WKJKBELXHCTHIJ-WPRPVWTQSA-N Gly-Arg-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N WKJKBELXHCTHIJ-WPRPVWTQSA-N 0.000 description 1
WEGGKZQIJMQCGR-RECQUVTISA-N Hemorphin-4 Chemical compound C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H]([C@H](O)C)C(O)=O)C1=CC=C(O)C=C1 WEGGKZQIJMQCGR-RECQUVTISA-N 0.000 description 1
MMFKFJORZBJVNF-UWVGGRQHSA-N His-Leu Chemical group CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CN=CN1 MMFKFJORZBJVNF-UWVGGRQHSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
DMHGKBGOUAJRHU-RVMXOQNASA-N Ile-Arg-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(=O)O)N DMHGKBGOUAJRHU-RVMXOQNASA-N 0.000 description 1
DMHGKBGOUAJRHU-UHFFFAOYSA-N Ile-Arg-Pro Natural products CCC(C)C(N)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(O)=O DMHGKBGOUAJRHU-UHFFFAOYSA-N 0.000 description 1
LNJLOZYNZFGJMM-DEQVHRJGSA-N Ile-His-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@@H]2C(=O)O)N LNJLOZYNZFGJMM-DEQVHRJGSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
125000002435 L-phenylalanyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
108010007859 Lisinopril Proteins 0.000 description 1
IPOLXDNCMOVXCP-YZVVJARPSA-N Lyciumin A Natural products O=C(N[C@H]1C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](C(=O)O)Cc2c3c(n1c2)cccc3)[C@H](NC(=O)[C@H]1N(C(=O)[C@@H]2NC(=O)CC2)CCC1)Cc1ccc(O)cc1 IPOLXDNCMOVXCP-YZVVJARPSA-N 0.000 description 1
IPOLXDNCMOVXCP-UHFFFAOYSA-N Lyciumin A Chemical compound C12=CC=CC=C2N2C=C1CC(C(O)=O)NC(=O)C(CO)NC(=O)CNC(=O)C(C(C)C)NC(=O)C2NC(=O)C(NC(=O)C1N(CCC1)C(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 IPOLXDNCMOVXCP-UHFFFAOYSA-N 0.000 description 1
BARYJIKIMHXXOI-UHFFFAOYSA-N Lyciumin A methylate Natural products O=C1NC(C(C)C)C(=O)NCC(=O)NC(CO)C(=O)NC(C(=O)OC)CC(C2=CC=CC=C22)=CN2C1NC(=O)C(NC(=O)C1N(CCC1)C(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BARYJIKIMHXXOI-UHFFFAOYSA-N 0.000 description 1
MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 description 1
UWWDHYUMIORJTA-HSQYWUDLSA-N Moexipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC(OC)=C(OC)C=C2C1)C(O)=O)CC1=CC=CC=C1 UWWDHYUMIORJTA-HSQYWUDLSA-N 0.000 description 1
NZFXQRHFBLVEQA-UHFFFAOYSA-N Muracein A Natural products NC(=O)C(N)CCCC(C(O)=O)NC(=O)CCC(C(O)=O)NC(=O)C(C)NC(=O)C(C)OC1C(O)C(CO)OC(O)C1NC(C)=O NZFXQRHFBLVEQA-UHFFFAOYSA-N 0.000 description 1
BNEJUCHZSDIIEH-UHFFFAOYSA-N Muracein B Natural products OC(=O)C(C)NC(=O)C(C)NC(=O)C(CCCC(N)C(N)=O)NC(=O)CCC(C(O)=O)NC(=O)C(C)NC(=O)C(C)OC1C(O)C(CO)OC(O)C1NC(C)=O BNEJUCHZSDIIEH-UHFFFAOYSA-N 0.000 description 1
238000011887 Necropsy Methods 0.000 description 1
206010029113 Neovascularisation Diseases 0.000 description 1
208000005890 Neuroma Diseases 0.000 description 1
208000031481 Pathologic Constriction Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
229940122985 Peptide agonist Drugs 0.000 description 1
206010034650 Peritoneal adhesions Diseases 0.000 description 1
XRKXJJYSKUIIEN-LLVKDONJSA-N Pivopril Chemical compound CC(C)(C)C(=O)SC[C@@H](C)C(=O)N(CC(O)=O)C1CCCC1 XRKXJJYSKUIIEN-LLVKDONJSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
ORPZXBQTEHINPB-SRVKXCTJSA-N Pro-Arg-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1)C(O)=O ORPZXBQTEHINPB-SRVKXCTJSA-N 0.000 description 1
101000781681 Protobothrops flavoviridis Disintegrin triflavin Proteins 0.000 description 1
UBTNVMGPMYDYIU-HJPIBITLSA-N Ser-Tyr-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O UBTNVMGPMYDYIU-HJPIBITLSA-N 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
108010045759 Teprotide Proteins 0.000 description 1
UUUHXMGGBIUAPW-CSCXCSGISA-N Teprotide Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(O)=O)C(=O)[C@@H]1CCC(=O)N1 UUUHXMGGBIUAPW-CSCXCSGISA-N 0.000 description 1
JRAUIKJSEAKTGD-TUBUOCAGSA-N Thr-Ile-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N JRAUIKJSEAKTGD-TUBUOCAGSA-N 0.000 description 1
108010064129 Thrombogen Proteins 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
NLPUTBDZNNXHCO-CGHBYZBKSA-N Val(5)-angiotensin II Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 NLPUTBDZNNXHCO-CGHBYZBKSA-N 0.000 description 1
GUIYPEKUEMQBIK-JSGCOSHPSA-N Val-Tyr-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(O)=O GUIYPEKUEMQBIK-JSGCOSHPSA-N 0.000 description 1
206010048031 Wound dehiscence Diseases 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
238000012084 abdominal surgery Methods 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
230000000758 acidotic effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
229950007884 alacepril Drugs 0.000 description 1
125000002723 alicyclic group Chemical group 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
108010055869 ancovenin Proteins 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
230000002491 angiogenic effect Effects 0.000 description 1
JYPVVOOBQVVUQV-CGHBYZBKSA-N angiotensinamide Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 JYPVVOOBQVVUQV-CGHBYZBKSA-N 0.000 description 1
108010058865 angiotensinase Proteins 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
108010092854 aspartyllysine Proteins 0.000 description 1
239000000305 astragalus gummifer gum Substances 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
210000002469 basement membrane Anatomy 0.000 description 1
229960004530 benazepril Drugs 0.000 description 1
229960003619 benazepril hydrochloride Drugs 0.000 description 1
VPSRQEHTHIMDQM-FKLPMGAJSA-N benazepril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 VPSRQEHTHIMDQM-FKLPMGAJSA-N 0.000 description 1
229960004067 benazeprilat Drugs 0.000 description 1
MADRIHWFJGRSBP-ROUUACIJSA-N benazeprilat Chemical compound C([C@H](N[C@H]1CCC2=CC=CC=C2N(C1=O)CC(=O)O)C(O)=O)CC1=CC=CC=C1 MADRIHWFJGRSBP-ROUUACIJSA-N 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
KKBIUAUSZKGNOA-HNAYVOBHSA-N benzyl (2s)-2-[[(2s)-2-(acetylsulfanylmethyl)-3-(1,3-benzodioxol-5-yl)propanoyl]amino]propanoate Chemical compound O=C([C@@H](NC(=O)[C@@H](CSC(C)=O)CC=1C=C2OCOC2=CC=1)C)OCC1=CC=CC=C1 KKBIUAUSZKGNOA-HNAYVOBHSA-N 0.000 description 1
IVBOFTGCTWVBLF-GOSISDBHSA-N benzyl 2-[[(2s)-2-(acetylsulfanylmethyl)-3-(1,3-benzodioxol-5-yl)propanoyl]amino]acetate Chemical compound O=C([C@H](CC=1C=C2OCOC2=CC=1)CSC(=O)C)NCC(=O)OCC1=CC=CC=C1 IVBOFTGCTWVBLF-GOSISDBHSA-N 0.000 description 1
229940064804 betadine Drugs 0.000 description 1
229960003237 betaine Drugs 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
230000036770 blood supply Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
244000309464 bull Species 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
CUZMQPZYCDIHQL-VCTVXEGHSA-L calcium;(2s)-1-[(2s)-3-[(2r)-2-(cyclohexanecarbonylamino)propanoyl]sulfanyl-2-methylpropanoyl]pyrrolidine-2-carboxylate Chemical compound [Ca+2].N([C@H](C)C(=O)SC[C@@H](C)C(=O)N1[C@@H](CCC1)C([O-])=O)C(=O)C1CCCCC1.N([C@H](C)C(=O)SC[C@@H](C)C(=O)N1[C@@H](CCC1)C([O-])=O)C(=O)C1CCCCC1 CUZMQPZYCDIHQL-VCTVXEGHSA-L 0.000 description 1
229960000830 captopril Drugs 0.000 description 1
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
229950005749 ceronapril Drugs 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000035605 chemotaxis Effects 0.000 description 1
210000003711 chorioallantoic membrane Anatomy 0.000 description 1
229960005025 cilazapril Drugs 0.000 description 1
HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 description 1
229950010233 cilazaprilat Drugs 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
230000008602 contraction Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
238000002316 cosmetic surgery Methods 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000006071 cream Substances 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
229960005227 delapril Drugs 0.000 description 1
WOUOLAUOZXOLJQ-MBSDFSHPSA-N delapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 WOUOLAUOZXOLJQ-MBSDFSHPSA-N 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
210000001951 dura mater Anatomy 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
229960000873 enalapril Drugs 0.000 description 1
GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 description 1
229960002680 enalaprilat Drugs 0.000 description 1
LZFZMUMEGBBDTC-QEJZJMRPSA-N enalaprilat (anhydrous) Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 LZFZMUMEGBBDTC-QEJZJMRPSA-N 0.000 description 1
108010049503 enalkiren Proteins 0.000 description 1
229950008153 enalkiren Drugs 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000035558 fertility Effects 0.000 description 1
229950003499 fibrin Drugs 0.000 description 1
239000012467 final product Substances 0.000 description 1
108010090705 foroxymithine Proteins 0.000 description 1
229960001880 fosinopril sodium Drugs 0.000 description 1
229960003018 fosinoprilat Drugs 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
229960003180 glutathione Drugs 0.000 description 1
229940074045 glyceryl distearate Drugs 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
NJZRLXNBGZBREL-UHFFFAOYSA-N glycine betaine hydrate Chemical compound [OH-].C[N+](C)(C)CC(O)=O NJZRLXNBGZBREL-UHFFFAOYSA-N 0.000 description 1
108010020688 glycylhistidine Proteins 0.000 description 1
239000008187 granular material Substances 0.000 description 1
108010047748 hemorphin 4 Proteins 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
230000002962 histologic effect Effects 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
239000005555 hypertensive agent Substances 0.000 description 1
229960001195 imidapril Drugs 0.000 description 1
KLZWOWYOHUKJIG-BPUTZDHNSA-N imidapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1C(N(C)C[C@H]1C(O)=O)=O)CC1=CC=CC=C1 KLZWOWYOHUKJIG-BPUTZDHNSA-N 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
229950009810 indolapril Drugs 0.000 description 1
208000000509 infertility Diseases 0.000 description 1
230000036512 infertility Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000007917 intracranial administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000029774 keratinocyte migration Effects 0.000 description 1
229960004184 ketamine hydrochloride Drugs 0.000 description 1
239000008101 lactose Substances 0.000 description 1
238000002684 laminectomy Methods 0.000 description 1
229950001218 libenzapril Drugs 0.000 description 1
AXTCRUUITQKBAV-KBPBESRZSA-N libenzapril Chemical compound OC(=O)CN1C(=O)[C@@H](N[C@@H](CCCCN)C(O)=O)CCC2=CC=CC=C21 AXTCRUUITQKBAV-KBPBESRZSA-N 0.000 description 1
239000000865 liniment Substances 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
229960002394 lisinopril Drugs 0.000 description 1
RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000000395 magnesium oxide Substances 0.000 description 1
CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
210000005033 mesothelial cell Anatomy 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
230000027939 micturition Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
229960005170 moexipril Drugs 0.000 description 1
229960000937 moexiprilat Drugs 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
229950006549 moveltipril Drugs 0.000 description 1
108700005507 muracein A Proteins 0.000 description 1
108700005515 muracein B Proteins 0.000 description 1
108700005514 muracein C Proteins 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
QWRYRQKHCGBRGW-NJJVJDFKSA-N n-[(3r,4r,5s,6r)-2,5-dihydroxy-6-(hydroxymethyl)-4-(1-oxopropan-2-yloxy)oxan-3-yl]acetamide Chemical compound O=CC(C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O QWRYRQKHCGBRGW-NJJVJDFKSA-N 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000002674 ointment Substances 0.000 description 1
230000000399 orthopedic effect Effects 0.000 description 1
239000006072 paste Substances 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
230000035515 penetration Effects 0.000 description 1
229950008492 pentopril Drugs 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
229960002582 perindopril Drugs 0.000 description 1
IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 1
229960005226 perindoprilat Drugs 0.000 description 1
ODAIHABQVKJNIY-PEDHHIEDSA-N perindoprilat Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(O)=O)[C@H]21 ODAIHABQVKJNIY-PEDHHIEDSA-N 0.000 description 1
210000004303 peritoneum Anatomy 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
235000011007 phosphoric acid Nutrition 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
229950008688 pivopril Drugs 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
229960001455 quinapril Drugs 0.000 description 1
JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
229960003042 quinapril hydrochloride Drugs 0.000 description 1
IBBLRJGOOANPTQ-JKVLGAQCSA-N quinapril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 IBBLRJGOOANPTQ-JKVLGAQCSA-N 0.000 description 1
229960001007 quinaprilat Drugs 0.000 description 1
FLSLEGPOVLMJMN-YSSFQJQWSA-N quinaprilat Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)C(O)=O)CC1=CC=CC=C1 FLSLEGPOVLMJMN-YSSFQJQWSA-N 0.000 description 1
229960003401 ramipril Drugs 0.000 description 1
HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
229960002231 ramiprilat Drugs 0.000 description 1
KEDYTOTWMPBSLG-HILJTLORSA-N ramiprilat Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)C(O)=O)CC1=CC=CC=C1 KEDYTOTWMPBSLG-HILJTLORSA-N 0.000 description 1
238000011552 rat model Methods 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
238000007634 remodeling Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
229940083542 sodium Drugs 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000010532 solid phase synthesis reaction Methods 0.000 description 1
241000894007 species Species 0.000 description 1
229950006297 spiraprilat Drugs 0.000 description 1
108700006892 spiraprilat Proteins 0.000 description 1
FMMDBLMCSDRUPA-BPUTZDHNSA-N spiraprilat Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](CC2(C1)SCCS2)C(O)=O)C(O)=O)CC1=CC=CC=C1 FMMDBLMCSDRUPA-BPUTZDHNSA-N 0.000 description 1
238000013223 sprague-dawley female rat Methods 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
235000011149 sulphuric acid Nutrition 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
229950010186 teprotide Drugs 0.000 description 1
208000037816 tissue injury Diseases 0.000 description 1
230000017423 tissue regeneration Effects 0.000 description 1
229960001017 tolmetin Drugs 0.000 description 1
UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
229960002051 trandolapril Drugs 0.000 description 1
AHYHTSYNOHNUSH-HXFGRODQSA-N trandolaprilat Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)C(O)=O)CC1=CC=CC=C1 AHYHTSYNOHNUSH-HXFGRODQSA-N 0.000 description 1
229960002651 trandolaprilat Drugs 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000014616 translation Effects 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
229950005696 utibapril Drugs 0.000 description 1
108010009962 valyltyrosine Proteins 0.000 description 1
238000005303 weighing Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
230000037314 wound repair Effects 0.000 description 1
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
229960001600 xylazine Drugs 0.000 description 1
229950009999 zabicipril Drugs 0.000 description 1
229950005973 zabiciprilat Drugs 0.000 description 1
229960002769 zofenopril Drugs 0.000 description 1
IAIDUHCBNLFXEF-MNEFBYGVSA-N zofenopril Chemical compound C([C@@H](C)C(=O)N1[C@@H](C[C@@H](C1)SC=1C=CC=CC=1)C(O)=O)SC(=O)C1=CC=CC=C1 IAIDUHCBNLFXEF-MNEFBYGVSA-N 0.000 description 1
UQWLOWFDKAFKAP-WXHSDQCUSA-N zofenoprilat Chemical compound C1[C@@H](C(O)=O)N(C(=O)[C@@H](CS)C)C[C@H]1SC1=CC=CC=C1 UQWLOWFDKAFKAP-WXHSDQCUSA-N 0.000 description 1
229950001300 zofenoprilat Drugs 0.000 description 1

Landscapes

Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA002442340A 1999-03-23 2000-03-22 Proceder pour limiter la formation de cicatrices et d'adherences Abandoned CA2442340A1 (fr)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US12570799P	1999-03-23	1999-03-23
US60/125,707		1999-03-23
US13954199P	1999-06-16	1999-06-16
US60/139,541		1999-06-16
CA002367107A CA2367107C (fr)	1999-03-23	2000-03-22	Procede pour limiter la formation de cicatrices et d'adherences

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002367107A Division CA2367107C (fr)	1999-03-23	2000-03-22	Procede pour limiter la formation de cicatrices et d'adherences

Publications (1)

Publication Number	Publication Date
CA2442340A1 true CA2442340A1 (fr)	2000-09-28

Family

ID=30448762

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002442340A Abandoned CA2442340A1 (fr)	1999-03-23	2000-03-22	Proceder pour limiter la formation de cicatrices et d'adherences

Country Status (1)

Country	Link
CA (1)	CA2442340A1 (fr)

2000
- 2000-03-22 CA CA002442340A patent/CA2442340A1/fr not_active Abandoned

Publication	Publication Date	Title
AU706333B2 (en)	1999-06-17	Use of angiotensin III and analogs thereof in tissue repair
AU713955B2 (en)	1999-12-16	Use of angiotensin II fragments and analogs thereof in tissue repair
CA2364484A1 (fr)	2000-09-14	Methode de stimulation de la proliferation de myocytes et de la reparation des tissus myocardiques
JP4347522B2 (ja)	2009-10-21	創傷治癒組成物
US6747008B1 (en)	2004-06-08	Methods for treating and preventing alopecia
US7786085B2 (en)	2010-08-31	Method for treating a patient undergoing chemotherapy
EP1333034A1 (fr)	2003-08-06	Utilisation d'analogues d'angiotensine II pour la réparation tissulaire
US6730775B1 (en)	2004-05-04	Methods for limiting scar and adhesion formation
WO1996014858A9 (fr)	1996-08-08	Utilisation de fragments d'angiotensine ii et d'analogues de celle-ci pour la reparation des tissus
US6821953B1 (en)	2004-11-23	Methods for treating and preventing damage to mucosal tissue
AU5990796A (en)	1996-12-24	Use of angiotensin II type 2 receptor agonists in tissue repair
CA2367107C (fr)	2003-10-14	Procede pour limiter la formation de cicatrices et d'adherences
US20020049162A1 (en)	2002-04-25	Methods for inhibiting smooth muscle cell proliferation
CA2393755C (fr)	2010-09-21	Procedes permettant de traiter et d'empecher des lesions des muqueuses
WO2001044270A2 (fr)	2001-06-21	Procedes permettant de traiter et d'empecher des complications diabetiques
EP1292610A1 (fr)	2003-03-19	Procedes de traitement et de prevention de l'alopecie
CA2442340A1 (fr)	2000-09-28	Proceder pour limiter la formation de cicatrices et d'adherences
CN1187133A (zh)	1998-07-08	血管紧张素ⅱ2型受体激动剂在组织修复中的应用

Legal Events

Date	Code	Title	Description
2006-03-22	FZDE	Dead